Lyme Borreliosis: A Possible Hidden Cause of Heart Block of Unknown Origin in Men with Pacemakers

Autor: Peeters, A. J., Sedney, M. I., Telgt, D., ten Wolde, S., Nohlmans, M. K. E., Blaauw, A. A. M., van der Linden, S., Dijkmans, B. A. C.

Publikováno v: The Journal of Infectious Diseases, 1991 Jul 01. 164(1), 220-221.

Externí odkaz: https://www.jstor.org/stable/30112910

Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID- treatment - A randomized, placebo controlled trial

Autor: Htji, Leest, Steen, K. S. S., Lems, W. F., Jwj, Bijlsma, Mafj, Laar, Am, Huisman, Vonkeman, H. E., Houben, H. H. M. L., Kadir, S. W., Kostense, P. J., Maurits van Tulder, Kuipers, E. J., Boers, M., Dijkmans, B. A. C.

Publikováno v: De Leest, HTJI, Steen, K S S, Lems, W F, Bijlsma, JWJ, Van de Laar, MAFJ, Huisman, AM, Vonkeman, H E, Houben, H H M L, Kadir, S W, Kostense, P J, van Tulder, MW, Kuipers, E J, Boers, M & Dijkmans, B A C 2004, ' Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID-treatment-A randomized, placebo controlled trial. ', Arthritis & Rheumatism, vol. 50, no. 9, pp. S459-S459 .
De Leest, HTJI, Steen, K S S, Lems, W F, Bijlsma, JWJ, Van de Laar, MAFJ, Huisman, AM, Vonkeman, H E, Houben, H H M L, Kadir, S W, Kostense, P J, van Tulder, MW, Kuipers, E J, Boers, M & Dijkmans, B A C 2004, ' Eradication of Helicobacter pylori does not reduce the incidence of gastroduodenal ulcers in patients on long-term NSAID-treatment-A randomized, placebo controlled trial. ' Arthritis & Rheumatism, vol. 50, no. 9, pp. S459-S459 .
Arthritis & Rheumatism, 50(9), S459-S459. John Wiley and Sons Inc.
Vrije Universiteit Amsterdam
Aarhus University

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::17a20c9b4483a71434f58e3657c8371d
https://hdl.handle.net/1871.1/5662ca36-661d-4f6c-a3f5-5252a6076bf7

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

Autor: Van der Heijde, D, Schiff, M. H, Sieper, J, Kivitz, A. J, Wong, R. L, Kupper, H, Dijkmans, B. A. C, Mease, P. J, Davis, J. C, Atlas, Salvarani, Carlo

Publikováno v: van der Heijde, D, Schiff, M H, Sieper, J, Kivitz, A J, Wong, R L, Kupper, H, Dijkmans, B A C, Mease, P J & Davis, J C 2009, ' Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial ', Annals of the Rheumatic Diseases, vol. 68, no. 6, pp. 922-929 . https://doi.org/10.1136/ard.2007.087270
Annals of the Rheumatic Diseases, 68(6), 922-929. BMJ Publishing Group
Annals of the Rheumatic Diseases

Objective: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in the Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo controlled, 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75da5fea970f34277f7b7101e26d4ca9
https://research.vumc.nl/en/publications/b9ca777b-e157-4eac-9e5c-418cdd67d58f

Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis

Autor: Bos, W. H., Bartelds, G. M., Gerrit Jan Wolbink, Koning, M. H. M. T., Stadt, R. J., Schaardenburg, D., Dijkmans, B. A. C., Nurmohamed, M. T.

Publikováno v: Journal of Rheumatology, 35(10), 1972-1977. Journal of Rheumatology
Scopus-Elsevier
Bos, W H, Bartelds, G M, Wolbink, G J, de Koning, M H, van de Stadt, R J, van Schaardenburg, D, Dijkmans, B A C & Nurmohamed, M T 2008, ' Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis ', Journal of Rheumatology, vol. 35, no. 10, pp. 1972-1977 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b36659baca73198ec76b75d747a3aa4a
https://research.vumc.nl/en/publications/f48c8769-a2e9-46fc-aa7e-8a98fee40bf7

IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis

Autor: Vis, M., Bos, W. H., Gerrit Jan Wolbink, Voskuyl, A. E., Twisk, J. W. R., Stadt, R., Hamann, D., Dijkmans, B. A. C., Lems, W. F.

Publikováno v: Journal of Rheumatology, 35(3), 425-428. Journal of Rheumatology
Scopus-Elsevier
Vis, M, Bos, W H, Wolbink, G, Voskuijl, A E, Twisk, J W R, van de Stadt, R, Hamann, D, Dijkmans, B A C & Lems, W F 2008, ' IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis ', Journal of Rheumatology, vol. 35, no. 3, pp. 425-428 .

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::56a78c0d9ff2ccc60a48a9675fe6f7a3
https://research.vumc.nl/en/publications/4845bc05-aa58-4d93-a50f-64b680079d09